Study Title:
A Phase 1 Study of ABI-009 (nab-Rapamycin) (IND# 133537) in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors as a Single Agent and in Combination with Temozolomide and Irinotecan
CIRB:
Lead Group:
Status:
Review Status: